Wolverine Trading
LXRX icon

Wolverine Trading’s Lexicon Pharmaceuticals LXRX Stock Holding History

Wolverine Trading’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$39.6K Buy
28,500
+7,400
+35% +$8.4K ﹤0.01% 5461
2025
Q2 		$17.3K Sell
21,100
-4,800
-19% -$3.11K ﹤0.01% 4477
2025
Q1 		$14.8K Buy
25,900
+8,400
+48% +$5.3K ﹤0.01% 4585
2024
Q4 		$12.6K Buy
17,500
+5,600
+47% +$6.75K ﹤0.01% 5142
2024
Q3 		$19K Sell
11,900
-7,100
-37% -$12.6K ﹤0.01% 4643
2024
Q2 		$31.9K Buy
+19,000
New +$34.1K ﹤0.01% 4282
2024
Q1 		– Sell
-33,400
Closed -$51.1K – 4937
2023
Q4 		$51.1K Buy
+33,400
New +$39.7K ﹤0.01% 4254
2023
Q2 		– Sell
-16,000
Closed -$37K – 4634
2023
Q1 		$37K Buy
16,000
+4,000
+33% +$9.17K ﹤0.01% 3894
2022
Q4 		$23K Buy
+12,000
New +$25.5K ﹤0.01% 3715
2022
Q3 		– Sell
-28,900
Closed -$65K – 5019
2022
Q2 		$65K Buy
28,900
+400
+1% +$763 ﹤0.01% 3988
2022
Q1 		$60K Sell
28,500
-1,100
-4% -$3.05K ﹤0.01% 5024
2021
Q4 		$123K Buy
29,600
+15,300
+107% +$74.3K ﹤0.01% 5002
2021
Q3 		$70K Sell
14,300
-12,600
-47% -$51.7K ﹤0.01% 5922
2021
Q2 		$135K Sell
26,900
-14,700
-35% -$70.8K ﹤0.01% 5256
2021
Q1 		$236K Buy
41,600
+8,800
+27% +$60.9K ﹤0.01% 4814
2020
Q4 		$109K Buy
32,800
+16,200
+98% +$30.9K ﹤0.01% 4443
2020
Q3 		$24K Buy
16,600
+3,200
+24% +$5.7K ﹤0.01% 4374
2020
Q2 		$27K Buy
+13,400
New +$26.3K ﹤0.01% 4407
2020
Q1 		– Sell
-18,700
Closed -$77K – 4989
2019
Q4 		$77K Sell
18,700
-1,400
-7% -$5.39K ﹤0.01% 4358
2019
Q3 		$69K Sell
20,100
-10,900
-35% -$33.7K ﹤0.01% 3967
2019
Q2 		$195K Buy
31,000
+5,600
+22% +$33.5K ﹤0.01% 3732
2019
Q1 		$141K Buy
+25,400
New +$154K ﹤0.01% 4014
2018
Q3 		– Sell
-11,000
Closed -$94K – 5466
2018
Q2 		$94K Hold
11,000
– – ﹤0.01% 4742
2018
Q1 		$94K Sell
11,000
-300
-3% -$2.77K ﹤0.01% 4742
2017
Q4 		$112K Sell
11,300
-4,300
-28% -$44.7K ﹤0.01% 4416
2017
Q3 		$192K Buy
+15,600
New +$230K ﹤0.01% 3835

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wolverine Trading's LXRX Position: Q3 2025 in Review

Wolverine Trading opened a new position in Lexicon Pharmaceuticals (LXRX) in Q3 2025: 21,191 shares worth $29.5K. The stake represents ﹤0.01% of the portfolio and ranks #5501 among its holdings. This is a return to the name: Wolverine Trading previously reported a position in LXRX as recently as Q3 2024.

Wolverine Trading first reported a position in LXRX in Q1 2019 and has held it in 13 quarters since. The position peaked at $202K in Q1 2019. 123 funds tracked by Wall St. Rank hold LXRX as of Q3 2025.

  • Wolverine Trading held 21,191 shares of Lexicon Pharmaceuticals worth $29.5K as of Q3 2025.
  • Lexicon Pharmaceuticals was a new Wolverine Trading position in Q3 2025.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5501 holding.
  • Wolverine Trading first reported a position in Lexicon Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
  • Wolverine Trading's Lexicon Pharmaceuticals position peaked at $202K in Q1 2019.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.